Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant

Executive Summary

Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.

Advertisement

Related Content

CHMP Clears Pierre Fabre’s Hemangiol For Children, Under Rarely Used Pediatric Pathway
Shire Plans New Cinryze Versions, Promises Fresh M&A And Innovation
Biopharma Dealmaking Quarterly Statistics, Q4 2013
Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge
Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration
ViroPharma Talks Cinryze Sales, EU Launches
Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr
Cinryze Approved To Prevent HAE Attacks
ViroPharma's Second Act: First a Tough One to Follow
Shire Shifts Upstream

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel